AKT1 and nasopharyngeal carcinoma: Additionally, it showed encouraging anti-tumour activity in acute myeloid leukaemia (AML) [81] and an ability to inhibit both AKT and mTOR signalling in nasopharyngeal carcinoma (NPC) cell lines [82].